RU2017101325A3 - - Google Patents

Download PDF

Info

Publication number
RU2017101325A3
RU2017101325A3 RU2017101325A RU2017101325A RU2017101325A3 RU 2017101325 A3 RU2017101325 A3 RU 2017101325A3 RU 2017101325 A RU2017101325 A RU 2017101325A RU 2017101325 A RU2017101325 A RU 2017101325A RU 2017101325 A3 RU2017101325 A3 RU 2017101325A3
Authority
RU
Russia
Application number
RU2017101325A
Other versions
RU2017101325A (ru
RU2733400C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017101325A publication Critical patent/RU2017101325A/ru
Publication of RU2017101325A3 publication Critical patent/RU2017101325A3/ru
Application granted granted Critical
Publication of RU2733400C2 publication Critical patent/RU2733400C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2017101325A 2014-06-17 2015-06-11 Производные пиразолопиридина в качестве ингибиторов киназы RU2733400C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1410815.3 2014-06-17
GBGB1410815.3A GB201410815D0 (en) 2014-06-17 2014-06-17 Therapeutic agents
PCT/EP2015/063048 WO2015193167A1 (en) 2014-06-17 2015-06-11 Pyrazolo-pyridine derivatives as kinase inhibitors

Publications (3)

Publication Number Publication Date
RU2017101325A RU2017101325A (ru) 2018-07-20
RU2017101325A3 true RU2017101325A3 (ru) 2019-01-17
RU2733400C2 RU2733400C2 (ru) 2020-10-01

Family

ID=51266751

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017101325A RU2733400C2 (ru) 2014-06-17 2015-06-11 Производные пиразолопиридина в качестве ингибиторов киназы

Country Status (11)

Country Link
US (1) US10087180B2 (ru)
EP (1) EP3157922B1 (ru)
JP (1) JP6602856B2 (ru)
CN (1) CN106459046B (ru)
BR (1) BR112016029635A2 (ru)
CA (1) CA2951419A1 (ru)
ES (1) ES2713403T3 (ru)
GB (1) GB201410815D0 (ru)
RU (1) RU2733400C2 (ru)
TR (1) TR201901338T4 (ru)
WO (1) WO2015193167A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201517263D0 (en) 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201521767D0 (en) 2015-12-10 2016-01-27 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R&D Therapeutic agents
EP3740489A1 (en) 2018-01-17 2020-11-25 GlaxoSmithKline Intellectual Property Development Limited Pi4kiiibeta inhibitors
TWI811428B (zh) 2018-08-21 2023-08-11 日商杏林製藥股份有限公司 雙環雜芳香環衍生物
US11578071B2 (en) 2019-10-04 2023-02-14 University Of Kentucky Research Foundation Preparation of pyrazolo[3,4-B]pyridines as antimalarials
US11767321B2 (en) 2020-10-05 2023-09-26 Enliven Inc. 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases
CN113603639B (zh) * 2021-09-07 2023-06-27 黑龙江立科新材料有限公司 2-氰基-5-溴吡啶的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106635A1 (en) * 2001-03-29 2004-06-03 Iwao Takamuro Spiroisoquinoline compound, a method for preparing the same and an intermediate thereof
JP2003252871A (ja) * 2001-03-29 2003-09-10 Tanabe Seiyaku Co Ltd スピロイソキノリン誘導体、その製法およびその合成中間体
RU2357967C2 (ru) * 2002-09-16 2009-06-10 Глаксо Груп Лимитед ПРОИЗВОДНЫЕ ПИРАЗОЛО[3, 4-b]ПИРИДИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ), ПРИМЕНЕНИЕ (ВАРИАНТЫ), КОМПОЗИЦИЯ (ВАРИАНТЫ)
EP1772454A4 (en) 2004-07-23 2009-02-25 Mitsubishi Tanabe Pharma Corp NITROGENIC CONDENSED BICYCLIC COMPOUND
JP2006056883A (ja) * 2004-07-23 2006-03-02 Tanabe Seiyaku Co Ltd 含窒素縮合二環式化合物およびその製法
DE602006005242D1 (de) * 2005-06-27 2009-04-02 Sanofi Aventis Pyrazolopyridinderivate als inhibitoren der kinase 1 des beta-adrenergen rezeptors
US8372842B2 (en) * 2008-01-09 2013-02-12 Array Biopharma Inc. Pyrazolopyridines as kinase inhibitors
EP2621923B1 (en) * 2010-09-29 2017-03-29 Intervet International B.V. N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases
GB201115665D0 (en) * 2011-09-09 2011-10-26 Univ Leuven Kath Autoimmune and inflammatory disorder therapy
SG10201703094UA (en) 2012-12-20 2017-06-29 Ucb Biopharma Sprl Therapeutically active pyrazolo-pyrimidine derivatives

Also Published As

Publication number Publication date
WO2015193167A1 (en) 2015-12-23
CA2951419A1 (en) 2015-12-23
CN106459046B (zh) 2019-01-08
GB201410815D0 (en) 2014-07-30
TR201901338T4 (tr) 2019-02-21
US20170121324A1 (en) 2017-05-04
EP3157922B1 (en) 2018-11-28
ES2713403T3 (es) 2019-05-21
JP6602856B2 (ja) 2019-11-06
US10087180B2 (en) 2018-10-02
JP2017518383A (ja) 2017-07-06
EP3157922A1 (en) 2017-04-26
CN106459046A (zh) 2017-02-22
RU2017101325A (ru) 2018-07-20
RU2733400C2 (ru) 2020-10-01
BR112016029635A2 (pt) 2017-08-22

Similar Documents

Publication Publication Date Title
BR112016027639A2 (ru)
BR112016021622A2 (ru)
BR112016016301A2 (ru)
BR112016016951A2 (ru)
BR112016016224A2 (ru)
BR112016018327A2 (ru)
BR112016015365A2 (ru)
BR112016019697A2 (ru)
BR112016020291A2 (ru)
BR112016020466A2 (ru)
BR112016022436A2 (ru)
BR112016030466A2 (ru)
BR112016022550A2 (ru)
BR112016019733A2 (ru)
RU2017101325A3 (ru)
BR112016025754A2 (ru)
BR112016030701A2 (ru)
BR112016023276A2 (ru)
BR112016023211A2 (ru)
BR112016018601A2 (ru)
BR112016026528A2 (ru)
BR112016027960A2 (ru)
BR112016022687A2 (ru)
CN302704121S (ru)
CN302700347S (ru)